343 related articles for article (PubMed ID: 22417295)
1. Costs of paediatric diabetes care in Germany: current situation and comparison with the year 2000.
Bächle CC; Holl RW; Straßburger K; Molz E; Chernyak N; Beyer P; Schimmel U; Rütschle H; Seidel J; Lepler R; Holder M; Rosenbauer J; Icks A; ;
Diabet Med; 2012 Oct; 29(10):1327-34. PubMed ID: 22417295
[TBL] [Abstract][Full Text] [Related]
2. Direct diabetes-related costs in young patients with early-onset, long-lasting type 1 diabetes.
Bächle C; Icks A; Straßburger K; Flechtner-Mors M; Hungele A; Beyer P; Placzek K; Hermann U; Schumacher A; Freff M; Stahl-Pehe A; Holl RW; Rosenbauer J;
PLoS One; 2013; 8(8):e70567. PubMed ID: 23967077
[TBL] [Abstract][Full Text] [Related]
3. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
4. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
von Ferber L; Köster I; Hauner H
Med Klin (Munich); 2006 May; 101(5):384-93. PubMed ID: 16685485
[TBL] [Abstract][Full Text] [Related]
5. Direct costs of pediatric diabetes care in Germany and their predictors.
Icks A; Rosenbauer J; Haastert B; Rathmann W; Grabert M; Gandjour A; Giani G; Holl RW
Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):302-9. PubMed ID: 15216447
[TBL] [Abstract][Full Text] [Related]
6. Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany.
Stock SA; Redaelli M; Wendland G; Civello D; Lauterbach KW
Diabet Med; 2006 Mar; 23(3):299-305. PubMed ID: 16492214
[TBL] [Abstract][Full Text] [Related]
7. Costs of treatment and complications of adult type 1 diabetes.
Franciosi M; Lucisano G; Amoretti R; Capani F; Bruttomesso D; Di Bartolo P; Girelli A; Leonetti F; Morviducci L; Vitacolonna E; Nicolucci A
Nutr Metab Cardiovasc Dis; 2013 Jul; 23(7):606-11. PubMed ID: 22749531
[TBL] [Abstract][Full Text] [Related]
8. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
[TBL] [Abstract][Full Text] [Related]
9. Direct costs in diabetic and non diabetic people: the population-based Turin study, Italy.
Bruno G; Picariello R; Petrelli A; Panero F; Costa G; Cavallo-Perin P; Demaria M; Gnavi R
Nutr Metab Cardiovasc Dis; 2012 Aug; 22(8):684-90. PubMed ID: 21907553
[TBL] [Abstract][Full Text] [Related]
10. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.
Pfohl M; Schädlich PK; Dippel FW; Koltermann KC
J Med Econ; 2012; 15 Suppl 2():14-27. PubMed ID: 22812690
[TBL] [Abstract][Full Text] [Related]
11. Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004.
van der Linden MW; Plat AW; Erkens JA; Emneus M; Herings RM
Value Health; 2009 Sep; 12(6):909-14. PubMed ID: 19508664
[TBL] [Abstract][Full Text] [Related]
12. Patient time costs attributable to healthcare use in diabetes: results from the population-based KORA survey in Germany.
Icks A; Claessen H; Strassburger K; Waldeyer R; Chernyak N; Jülich F; Rathmann W; Thorand B; Meisinger C; Huth C; Rückert IM; Schunk M; Giani G; Holle R
Diabet Med; 2013 Oct; 30(10):1245-9. PubMed ID: 23796224
[TBL] [Abstract][Full Text] [Related]
13. Insulin therapy for diabetes mellitus: treatment regimens and associated costs.
Charbonnel B; Penfornis A; Varroud-Vial M; Kusnik-Joinville O; Detournay B
Diabetes Metab; 2012 Apr; 38(2):156-63. PubMed ID: 22172400
[TBL] [Abstract][Full Text] [Related]
14. Technology and the issue of cost/benefit in diabetes.
Giannini C; Mohn A; Chiarelli F
Diabetes Metab Res Rev; 2009 Sep; 25 Suppl 1():S34-44. PubMed ID: 19662616
[TBL] [Abstract][Full Text] [Related]
15. Insulin pump therapy in childhood diabetes-cost implications for Primary Care Trusts.
Feltbower RG; Campbell FM; Bodansky HJ; Stephenson CR; McKinney PA
Diabet Med; 2006 Jan; 23(1):86-9. PubMed ID: 16409571
[TBL] [Abstract][Full Text] [Related]
16. [A cost of illness study of diabetes mellitus].
von Ferber L; Köster I; Hauner H
Gesundheitswesen; 1997 Jan; 59(1):17-22. PubMed ID: 9138642
[TBL] [Abstract][Full Text] [Related]
17. Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen.
Gundgaard J; Christensen TE; Thomsen TL
Prim Care Diabetes; 2010 Oct; 4(3):165-72. PubMed ID: 20452847
[TBL] [Abstract][Full Text] [Related]
18. Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study.
Liebl A; Breitscheidel L; Nicolay C; Happich M
Curr Med Res Opin; 2008 Aug; 24(8):2349-58. PubMed ID: 18606055
[TBL] [Abstract][Full Text] [Related]
19. [Costs of type 2 diabetes in Germany. Results of the CODE-2 study].
Liebl A; Neiss A; Spannheimer A; Reitberger U; Wagner T; Görtz A
Dtsch Med Wochenschr; 2001 May; 126(20):585-9. PubMed ID: 11402924
[TBL] [Abstract][Full Text] [Related]
20. Prevailing therapeutic regimes and predictive factors for prandial insulin substitution in 26 687 children and adolescents with Type 1 diabetes in Germany and Austria.
Knerr I; Hofer SE; Holterhus PM; Näke A; Rosenbauer J; Weitzel D; Wolf J; Holl RW
Diabet Med; 2007 Dec; 24(12):1478-81. PubMed ID: 17971184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
